WFX-003

WFX-003 is a preclinical-stage cell therapy candidate being developed by Walking Fish Therapeutics for the treatment of solid tumors. The therapy utilizes the company's proprietary platform to engineer B cells, which are designed to provide therapeutic anti-tumor activity. While the specific molecular target and detailed mechanism of action have not been disclosed, the approach generally involves leveraging B cells as protein factories to produce therapeutic proteins or to modulate the immune microenvironment within tumors. This platform aims to harness the unique capabilities of B cells, such as their ability to produce high levels of proteins and interact with other components of the immune system, to address challenges in treating solid malignancies.